JP2007514750A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007514750A5 JP2007514750A5 JP2006545436A JP2006545436A JP2007514750A5 JP 2007514750 A5 JP2007514750 A5 JP 2007514750A5 JP 2006545436 A JP2006545436 A JP 2006545436A JP 2006545436 A JP2006545436 A JP 2006545436A JP 2007514750 A5 JP2007514750 A5 JP 2007514750A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- ischemic
- composition according
- subject
- treprostinil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 claims description 8
- 229960005032 treprostinil Drugs 0.000 claims description 7
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 19
- 230000007654 ischemic lesion Effects 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 3
- 238000001802 infusion Methods 0.000 claims 3
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 206010043540 Thromboangiitis obliterans Diseases 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 208000013435 necrotic lesion Diseases 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 3
- 206010034576 Peripheral ischaemia Diseases 0.000 description 3
- 208000035901 Ischaemic ulcer Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000030613 peripheral artery disease Diseases 0.000 description 2
- IQKAWAUTOKVMLE-ZSESPEEFSA-M treprostinil sodium Chemical compound [Na+].C1=CC=C(OCC([O-])=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 IQKAWAUTOKVMLE-ZSESPEEFSA-M 0.000 description 2
- 206010049927 Dry gangrene Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940118867 remodulin Drugs 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960001726 treprostinil sodium Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52962203P | 2003-12-16 | 2003-12-16 | |
| US60/529,622 | 2003-12-16 | ||
| PCT/US2004/042283 WO2005058303A1 (en) | 2003-12-16 | 2004-12-16 | Use of treprostinil to treat and prevent ischemic lesions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012217695A Division JP2013047235A (ja) | 2003-12-16 | 2012-09-28 | 虚血性病変の治療および予防のためのトレプロスチニルの用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007514750A JP2007514750A (ja) | 2007-06-07 |
| JP2007514750A5 true JP2007514750A5 (https=) | 2012-06-21 |
| JP5190200B2 JP5190200B2 (ja) | 2013-04-24 |
Family
ID=34700011
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006545436A Expired - Fee Related JP5190200B2 (ja) | 2003-12-16 | 2004-12-16 | 虚血性病変の治療および予防のためのトレプロスチニルの用途 |
| JP2012217695A Pending JP2013047235A (ja) | 2003-12-16 | 2012-09-28 | 虚血性病変の治療および予防のためのトレプロスチニルの用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012217695A Pending JP2013047235A (ja) | 2003-12-16 | 2012-09-28 | 虚血性病変の治療および予防のためのトレプロスチニルの用途 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8765813B2 (https=) |
| EP (1) | EP1696900B1 (https=) |
| JP (2) | JP5190200B2 (https=) |
| KR (1) | KR101161889B1 (https=) |
| CN (2) | CN1917866B (https=) |
| AT (1) | ATE473736T1 (https=) |
| CA (1) | CA2549724C (https=) |
| DE (1) | DE602004028155D1 (https=) |
| ES (1) | ES2347254T3 (https=) |
| WO (1) | WO2005058303A1 (https=) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101265226B (zh) | 2003-05-22 | 2013-04-24 | 联合治疗公司 | 化合物和释放前列环素类似物的方法 |
| CA2549801C (en) * | 2003-12-16 | 2012-10-16 | United Therapeutics Corporation | Use of treprostinil to improve kidney functions |
| CN1917866B (zh) * | 2003-12-16 | 2010-12-15 | 联合治疗公司 | 曲前列环素或它的衍生物，或其药学上可接受的盐在制备治疗和预防缺血性损害的药物中的用途 |
| ATE462427T1 (de) | 2004-04-12 | 2010-04-15 | United Therapeutics Corp | Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren |
| US8747897B2 (en) * | 2006-04-27 | 2014-06-10 | Supernus Pharmaceuticals, Inc. | Osmotic drug delivery system |
| CN101495122B (zh) | 2006-05-15 | 2011-10-05 | 联合治疗公司 | 使用定量吸入器给予曲前列尼 |
| DE102006026786A1 (de) | 2006-06-07 | 2007-12-13 | Joachim Kern | Dosierinhalator |
| KR20160048222A (ko) | 2007-12-17 | 2016-05-03 | 유나이티드 세러퓨틱스 코오포레이션 | 레모둘린?의 활성 성분인 트레프로스티닐의 개선된 제조 방법 |
| US8350079B2 (en) * | 2008-05-08 | 2013-01-08 | United Therapeutics Corporation | Treprostinil formulation |
| JP5649645B2 (ja) * | 2009-05-07 | 2015-01-07 | ユナイテッド セラピューティクス コーポレイション | プロスタサイクリンアナログの固形製剤 |
| EP3108888B1 (en) | 2010-03-15 | 2020-02-12 | United Therapeutics Corporation | Treatment for pulmonary hypertension |
| WO2011153363A1 (en) | 2010-06-03 | 2011-12-08 | United Therapeutics Corporation | Treprostinil production |
| WO2011159693A2 (en) * | 2010-06-15 | 2011-12-22 | United Therapeutics Corporation | Oral treatment of digital ischemic lesions |
| EP2681204B1 (en) | 2011-03-02 | 2016-04-27 | United Therapeutics Corporation | Synthesis of intermediate for treprostinil production |
| CN103193626B (zh) | 2012-01-10 | 2016-05-11 | 上海天伟生物制药有限公司 | 一种前列腺素类似物的晶型及其制备方法和用途 |
| CN103193627B (zh) | 2012-01-10 | 2016-04-20 | 上海天伟生物制药有限公司 | 一种前列腺素类似物的晶型及其制备方法和用途 |
| CA2880808C (en) * | 2012-08-01 | 2023-01-24 | United Therapeutics Corporation | Treatment of pulmonary arterial hypertension with mesenchymal stem cells |
| ES2869701T3 (es) | 2012-08-01 | 2021-10-25 | United Therapeutics Corp | Tratamiento de hipertensión arterial pulmonar con células progenitoras endoteliales tratadas con prostaciclina |
| JP6431850B2 (ja) | 2013-01-09 | 2018-11-28 | ユナイテッド セラピューティクス コーポレイション | プロスタサイクリンおよび間葉系幹細胞による脈管障害の処置 |
| EP3712142B1 (en) | 2013-01-11 | 2022-07-06 | Corsair Pharma, Inc. | Prodrugs of treprostinil |
| US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| EP2970091A4 (en) | 2013-03-14 | 2017-02-08 | United Therapeutics Corporation | Solid forms of treprostinil |
| US20140275616A1 (en) | 2013-03-15 | 2014-09-18 | United Therapeutics Corporation | Salts of treprostinil |
| EP2978313B1 (en) | 2013-03-25 | 2018-02-21 | United Therapeutics Corporation | Process of making prostacyclin compounds with linker thiol and pegylated forms |
| FR3008320B1 (fr) * | 2013-07-15 | 2018-04-20 | Centre Hospitalier Univ Grenoble | Dispositif de prevention ou de traitement d'une ulceration cutanee |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| LT3060041T (lt) | 2013-10-25 | 2021-03-25 | Insmed Incorporated | Prostaciklino junginiai |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| CN106573066A (zh) | 2014-06-13 | 2017-04-19 | 联合治疗学有限公司 | 曲前列环素制剂 |
| CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| ES2778274T3 (es) | 2014-10-20 | 2020-08-10 | United Therapeutics Corp | Síntesis de productos intermedios para producir derivados de prostaciclina |
| WO2016064873A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| JP6866043B2 (ja) | 2014-11-18 | 2021-04-28 | インスメッド インコーポレイテッド | トレプロスチニルプロドラッグおよびトレプロスチニル誘導体プロドラッグの製造方法 |
| IL252577B (en) | 2014-12-03 | 2022-07-01 | Steadymed Ltd | Preservative-free treprostinil formulations and methods and devices for use with same |
| US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US9643911B2 (en) | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| JO3749B1 (ar) * | 2015-08-27 | 2021-01-31 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
| US10898494B2 (en) | 2016-05-05 | 2021-01-26 | Liquidia Technologies, Inc. | Dry powder treprostinil for the treatment of pulmonary hypertension |
| JP7220650B2 (ja) | 2016-09-26 | 2023-02-10 | ユナイテッド セラピューティクス コーポレイション | トレプロスチニルプロドラッグ |
| ES2927406T3 (es) | 2016-10-24 | 2022-11-04 | United Therapeutics Corp | Potenciación de las propiedades inmunomoduladoras de las MSC mediante treprostinil |
| US20190290597A1 (en) * | 2016-12-05 | 2019-09-26 | Corsair Pharma, Inc. | Dermal and transdermal administration of treprostinil and salts thereof |
| US10799653B2 (en) | 2017-01-09 | 2020-10-13 | United Therapeutics Corporation | Aerosol delivery device and method for manufacturing and operating the same |
| AU2019344541B2 (en) | 2018-09-18 | 2022-01-06 | Eli Lilly And Company | Erbumine salt of treprostinil |
| JP7455144B2 (ja) | 2019-04-29 | 2024-03-25 | インスメッド インコーポレイテッド | トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法 |
| JP2022546314A (ja) | 2019-08-23 | 2022-11-04 | ユナイテッド セラピューティクス コーポレイション | トレプロスチニルプロドラッグ |
| AU2021255621A1 (en) | 2020-04-17 | 2022-10-20 | United Therapeutics Corporation | Treprostinil for use in the treatment of intersitial lung disease |
| JP7608480B2 (ja) | 2020-06-09 | 2025-01-06 | ユナイテッド セラピューティクス コーポレイション | トレプロスチニルのフマリルジケトピペリジンプロドラッグ |
| WO2022132655A1 (en) | 2020-12-14 | 2022-06-23 | United Therapeutics Corporation | Methods of treating disease with treprostinil prodrugs |
| AU2022229367A1 (en) | 2021-03-03 | 2023-09-14 | United Therapeutics Corporation | A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp) |
| US20230263807A1 (en) | 2022-02-08 | 2023-08-24 | United Therapeutics Corporation | Treprostinil iloprost combination therapy |
| KR20250002687A (ko) | 2022-04-29 | 2025-01-07 | 자오커 파마슈티컬 (광저우) 컴퍼니., 리미티드 | 트레프로스티닐 소프트 미스트 흡입제 |
| JP2026503509A (ja) | 2023-01-18 | 2026-01-29 | ユナイテッド セラピューティクス コーポレイション | 肺動脈性肺高血圧症の治療 |
| AU2024208919A1 (en) | 2023-01-19 | 2025-07-17 | United Therapeutics Corporation | Treprostinil analogs |
| US20250049743A1 (en) | 2023-08-08 | 2025-02-13 | United Therapeutics Corporation | Method of producing an oral osmotic pharmaceutical delivery system and a pharmaceutical batch produced using the same |
| US20250197338A1 (en) | 2023-11-09 | 2025-06-19 | United Therapeutics Corporation | Syntheses of compounds useful for producing treprostinil |
| WO2026035705A1 (en) | 2024-08-06 | 2026-02-12 | United Therapeutics Corporation | Treating pulmonary hypertension based on novel biomarker |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4254145A (en) * | 1978-08-16 | 1981-03-03 | American Cyanamid Company | Topical application of prostaglandin hypotensive agents |
| DE2845770A1 (de) * | 1978-10-19 | 1980-04-30 | Schering Ag | Neue prostacyclin-derivate und verfahren zu ihrer herstellung |
| US4281113A (en) * | 1979-07-31 | 1981-07-28 | The Upjohn Company | 2,5-Inter-o-phenylene-3,4-dinor-6,9α-epoxy-6.beta.-5-iodo-PGF1 compounds |
| CA1201712A (en) | 1980-02-28 | 1986-03-11 | Paul A. Aristoff | Carbacyclin analogs |
| US4338457A (en) * | 1980-02-28 | 1982-07-06 | The Upjohn Company | Composition and process |
| US4306075A (en) * | 1980-03-28 | 1981-12-15 | The Upjohn Company | Composition and process |
| US4306076A (en) * | 1980-04-23 | 1981-12-15 | The Upjohn Company | Inter-phenylene CBA compounds |
| DE3048906A1 (de) * | 1980-12-19 | 1982-07-15 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US4349689A (en) * | 1980-12-22 | 1982-09-14 | The Upjohn Company | Methano carbacyclin analogs |
| US4486598A (en) * | 1982-02-22 | 1984-12-04 | The Upjohn Company | Carbacyclin analogs |
| ZA851337B (en) | 1984-03-08 | 1985-10-30 | Upjohn Co | Interphenylene carbacyclin derivatives |
| US4668814A (en) * | 1984-03-08 | 1987-05-26 | The Upjohn Company | Interphenylene carbacyclin derivatives |
| US4683330A (en) * | 1984-03-08 | 1987-07-28 | The Upjohn Company | Interphenylene carbacyclin derivatives |
| CA1241324A (en) | 1984-03-08 | 1988-08-30 | Paul A. Aristoff | Interphenylene carbacyclin derivatives |
| DE3686025T2 (de) * | 1985-05-22 | 1993-01-07 | Liposome Technology Inc | Verfahren und system zum einatmen von liposomen. |
| GB8814438D0 (en) * | 1988-06-17 | 1988-07-20 | Wellcome Found | Compounds for use in medicine |
| KR0158870B1 (ko) | 1988-06-17 | 1998-12-01 | 마틴 에이. 로쓰블랫 | 폐순환 승압의 치료, 예방 또는 진단용 조성물 |
| GB9011588D0 (en) | 1990-05-24 | 1990-07-11 | Wellcome Found | Prostaglandin analogues for use in medicine |
| US5190972A (en) * | 1992-01-27 | 1993-03-02 | The University Of Melbourne | Method of combatting cyclosporine organ toxicity with prostaglandin analogs |
| AU735975B2 (en) | 1995-02-27 | 2001-07-19 | Toray Industries, Inc. | Remedy for pulmonary heart |
| US6441245B1 (en) * | 1997-10-24 | 2002-08-27 | United Therapeutics Corporation | Process for stereoselective synthesis of prostacyclin derivatives |
| EP1045695B1 (en) * | 1997-11-14 | 2004-03-24 | United Therapeutics Corporation | Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f 1? to treat peripheral vascular disease |
| US6521212B1 (en) * | 1999-03-18 | 2003-02-18 | United Therapeutics Corporation | Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation |
| CN1354622A (zh) | 1999-03-31 | 2002-06-19 | 联合治疗公司 | 前列腺素类化合物、组合物和治疗外周血管疾病和肺动脉高压的方法 |
| JP2003501092A (ja) * | 1999-06-07 | 2003-01-14 | エドワーズ ライフサイエンシーズ コーポレイション | 標的化新脈管形成 |
| AU2002339730A1 (en) * | 2002-08-28 | 2004-03-19 | Universita "Campus Bio-Medico" Di Roma | Use of prostacyclin and analogs thereof for improving venous flow |
| US7550133B2 (en) * | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
| CN101265226B (zh) * | 2003-05-22 | 2013-04-24 | 联合治疗公司 | 化合物和释放前列环素类似物的方法 |
| US20040265238A1 (en) * | 2003-06-27 | 2004-12-30 | Imtiaz Chaudry | Inhalable formulations for treating pulmonary hypertension and methods of using same |
| CN1917866B (zh) * | 2003-12-16 | 2010-12-15 | 联合治疗公司 | 曲前列环素或它的衍生物，或其药学上可接受的盐在制备治疗和预防缺血性损害的药物中的用途 |
| ATE462427T1 (de) * | 2004-04-12 | 2010-04-15 | United Therapeutics Corp | Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren |
-
2004
- 2004-12-16 CN CN2004800417809A patent/CN1917866B/zh not_active Expired - Fee Related
- 2004-12-16 KR KR1020067013988A patent/KR101161889B1/ko not_active Expired - Fee Related
- 2004-12-16 WO PCT/US2004/042283 patent/WO2005058303A1/en not_active Ceased
- 2004-12-16 CN CN2009101645686A patent/CN101647792B/zh not_active Expired - Fee Related
- 2004-12-16 AT AT04814462T patent/ATE473736T1/de not_active IP Right Cessation
- 2004-12-16 CA CA2549724A patent/CA2549724C/en not_active Expired - Fee Related
- 2004-12-16 US US11/012,723 patent/US8765813B2/en active Active
- 2004-12-16 EP EP04814462A patent/EP1696900B1/en not_active Expired - Lifetime
- 2004-12-16 ES ES04814462T patent/ES2347254T3/es not_active Expired - Lifetime
- 2004-12-16 JP JP2006545436A patent/JP5190200B2/ja not_active Expired - Fee Related
- 2004-12-16 DE DE602004028155T patent/DE602004028155D1/de not_active Expired - Lifetime
-
2012
- 2012-09-28 JP JP2012217695A patent/JP2013047235A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007514750A5 (https=) | ||
| CA2562614C (en) | Use of treprostinil to treat neuropathic diabetic foot ulcers | |
| US8765813B2 (en) | Use of treprostinil to treat and prevent ischemic lesions | |
| JP2005501110A5 (https=) | ||
| JP2007532663A5 (https=) | ||
| ES2922551T3 (es) | Tratamiento de pacientes con diabetes mellitus tipo 2 | |
| JP2002528502A5 (https=) | ||
| JPS6169722A (ja) | 医薬用組成物 | |
| EP4494701A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| JP2020510043A5 (https=) | ||
| JP2002530353A5 (https=) | ||
| JP2002544227A5 (https=) | ||
| CA2474430A1 (en) | A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction | |
| Engel et al. | Treprostinil for the treatment of severe digital necrosis in systemic sclerosis | |
| CA2474703A1 (en) | Therapeutic agent of glaucoma comprising bunazosin and prostaglandins | |
| CA2414352A1 (en) | Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies | |
| JP2002529515A5 (https=) | ||
| JP2001058949A (ja) | 抗ショック剤 | |
| CA2515259A1 (en) | Use of acetylsalicylic acid for the treatment of hemorrhoidal disease | |
| RU2025131205A (ru) | Производные имидазотриазина в качестве модуляторов il-17 | |
| RU2025131206A (ru) | Производные имидазотриазина в качестве модуляторов il-17 | |
| Hossman | Eicosanoids in peripheral vascular disease | |
| JPS5920221A (ja) | レイノ−症状の改善・治療剤 | |
| TW202617156A (zh) | 用於治療進行性纖維化間質性肺病之新穎口服醫藥組合物及劑量療法 | |
| TW202615042A (zh) | 用於治療進行性纖維化間質性肺病之新穎治療組合 |